RecruitingPHASE1, PHASE2NCT06810544
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Studying Embryonal carcinoma of the central nervous system
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tango Therapeutics, Inc.
- Principal Investigator
- Tab Cooney, MDTango Therapeutics, Inc.
- Intervention
- TNG456(drug)
- Enrollment
- 191 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (13)
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- University of California, Irvine, Irvine, California, United States
- Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic Cancer Center, Rochester, Minnesota, United States
- NYU Langone Health, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
- NEXT Virginia, Fairfax, Virginia, United States
Collaborators
Eli Lilly and Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06810544 on ClinicalTrials.gov